

Onset and Duration of Adverse Events in Patients Treated With Fenfluramine in the Lennox-Gastaut Syndrome Clinical Trials

Lieven Lagae, MD, PhD, FRCP^{1,2}, Joseph Sullivan, MD³, Raman Sankar, MD, PhD⁴, Kelly G. Knupp, MD⁵, Sameer M. Zuberi, MD^{6,7,8}, Antonio Gil-Nagel, MD, PhD⁹, Ingrid E. Scheffer, MBBS, PhD, FRACP, FRS^{10,11,12,13}, Renzo Guerrini, MD, FRCP^{14,15}, Adam Strzelczyk, MD, MHBA, FEAN^{16,17}, Kate Riney, MB BCh BAO, PhD^{18,19,20}, Patrick Healy²¹, Jayne Abraham, PhD²¹, Mélanie Langlois, PhD²², Amélie Lothe, PhD²², Rima Nabbout, MD, PhD^{23,24,25}

¹University of Leuven, Leuven, Belgium; ²Leuven Childhood Epilepsy Center, Leuven Brain Institute, UZ Leuven, Member of the European Reference Network (ERN) EpiCARE, Leuven, Belgium; ³University of California San Francisco Weill Institute for Neuroscience, Benioff Children's Hospital, San Francisco, CA, USA; ⁴David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA; ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, USA; ⁶Paediatric Neurosciences Research Group, School of Health & Wellbeing, University of Glasgow, Glasgow, UK; ⁷Royal Hospital for Children, Glasgow, UK; ⁸Queen Elizabeth University Hospital, Member of the ERN EpiCARE, Glasgow, UK; ⁹Hospital Ruber Internacional, Madrid, Spain; ¹⁰University of Melbourne, Austin Health, Heidelberg, Victoria, Australia; ¹¹The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia; ¹²University of Melbourne, Royal Children's Hospital, Parkville, Victoria, Australia; ¹³Murdoch Children's Research Institute, Parkville, Victoria, Australia; ¹⁴Meyer Children's Hospital IRCCS, Member of the ERN EpiCARE, Florence, Italy; ¹⁵University of Florence, Florence, Italy; ¹⁶Goethe University Frankfurt, Epilepsy Center Frankfurt Rhine-Main, Frankfurt am Main, Germany; ¹⁷University Hospital Frankfurt, Frankfurt am Main, Germany; ¹⁸The University of Queensland, St Lucia, QLD, 4067, Australia; ¹⁹Queensland Children's Hospital, South Brisbane, QLD, 4101, Australia; ²⁰Children's Health Queensland, Queensland Hospital and Health Service, South Brisbane, QLD, 4101, Australia; ²¹UCB, Smyrna, GA, USA; ²²UCB, Colombes, France; ²³Reference Centre for Rare Epilepsies, Hôpital Universitaire Neckers-Enfants Malades, APHP, Member of the ERN EpiCARE, Paris, France; ²⁴Institut Imagine, U 1163, Paris, France; ²⁵Université Paris Cité, Paris, France

Introduction

- Lennox-Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy characterized by drug resistant seizures of multiple types^{1,2}
- There are a range of anti-seizure medications (ASMs) available that vary in mechanism of action, efficacy, and safety and tolerability³
- Since a patient-focused approach involves a balance of ASM safety and efficacy, understanding adverse event (AE) characteristics is important for providers, patients and families³
- Fenfluramine (FFA) is currently approved for the management of seizures associated with LGS in the US in patients ≥2 years old,⁴ and as add-on treatment for patients ≥2 years old with seizures associated with LGS in the EU, UK, Japan, and Israel⁵⁻⁸
- The FFA LGS clinical trial program involves a phase 3 trial of two parts: a randomized controlled trial (RCT)⁹ and open-label extension (OLE)¹⁰ (NCT03355209)


Objective

- This post hoc analysis describes the time of onset and duration of treatment emergent adverse events (TEAEs) reported in the FFA RCT and OLE

Methods

- In the RCT, patients with LGS (aged 2–35 years) enrolled from study sites in North America, Europe, and Australia were randomized to FFA 0.2 mg/kg/day or FFA 0.7 mg/kg/day (maximum 26 mg/day) or placebo
- After 2 weeks titration and 12 weeks maintenance in the RCT, patients could enroll in the OLE part where they were transitioned to FFA 0.2 mg/kg/day for 1 month, then were flexibly titrated to effect and tolerability ≥Month 2 (see overview in **Figure 1**)
 - Changes in concomitant ASMs were not permitted during the RCT
 - In the OLE, patients must have remained on a stable ASM regimen, including ≥1 concomitant ASM, for the first 6 months of the study; decreases in doses or discontinuation of ASMs were allowed after Month 6 but treatment with ≥1 concomitant ASM was required

Figure 1. FFA LGS RCT and OLE Study Overview



FFA, fenfluramine; LGS, Lennox-Gastaut syndrome; OLE, open-label extension; RCT, randomized controlled trial.

- For this post hoc analysis, the following were evaluated:
 - Incidence of TEAEs occurring in ≥10% of patients in the RCT and OLE (previously reported,^{9,10} reviewed in **Table 1**) by week of first onset of first occurrence
 - In the RCT, median time to onset and duration of first occurrences of TEAEs occurring in ≥10% of patients were reported by dose groups
 - Median time to onset of first occurrence of TEAEs occurring in ≥10% of patients in the OLE (any dose) and percent of patients in whom resolution of those TEAEs were reported

Table 1. Overview of TEAEs Occurring in ≥10% of Patients per Treatment Group in the RCT and Any Dose in the OLE

FFA Study	Treatment Group	Patients With ≥1 TEAE Reported, n (%)	Patients With TEAEs Occurring in ≥10% of Patients Reported, n (%)	TEAEs Reported in ≥10% of Patients
LGS RCT ^{9,11}	Placebo (n=87)	65 (74.7)	35 (40.2)	<ul style="list-style-type: none"> Decreased appetite (11.5%) Pyrexia (11.5%) Somnolence (10.3%) Fatigue (10.3%)
	FFA 0.2 mg/kg/day (n=89)	69 (77.5)	42 (47.2)	<ul style="list-style-type: none"> Decreased appetite (20.2%) Vomiting (13.5%) Diarrhea (11.2%) Pyrexia (10.1%) Somnolence (10.1%)
	FFA 0.7 mg/kg/day (n=87)	78 (89.7)	52 (59.8)	<ul style="list-style-type: none"> Decreased appetite (35.6%) Fatigue (18.4%) Somnolence (17.2%) Diarrhea (12.6%)
LGS OLE ¹⁰	Any dose (N=247)	203 (82.2)	127 (51.4)	<ul style="list-style-type: none"> Decreased appetite (16.2%) Fatigue (13.4%) Nasopharyngitis (12.6%) Seizure (10.9%)

FFA, fenfluramine; LGS, Lennox-Gastaut syndrome; OLE, open-label extension; RCT, randomized controlled trial; TEAE, treatment emergent adverse event.

Overview



QUESTION

What data are available related to the onset and duration of treatment emergent adverse events (TEAEs) reported in the clinical trials of fenfluramine (FFA) in patients with Lennox-Gastaut syndrome (LGS)?



INVESTIGATION

The safety and effectiveness of FFA were evaluated in previously published studies, specifically a 14-week randomized controlled trial (RCT) and subsequent open-label extension (OLE) study (NCT03355209). This post hoc analysis of those studies describes the time of onset and duration of TEAEs reported in ≥10% of patients in those studies.



RESULTS

- TEAEs reported in ≥10% of patients per randomized treatment group of the RCT, median time to onset, and proportion of patients with resolution of first occurrence of those TEAEs are described in the **Table**
- In the OLE, TEAEs reported in ≥10% of patients included: decreased appetite (16.2%), fatigue (13.4%), nasopharyngitis (12.6%), and seizure (10.9%); percent of patients with resolution of first occurrence is described in the **Figure**

Table. Median Time to Onset and Proportion of Patients With Resolution of First Occurrences of TEAEs Reported in ≥10% of Patients in the FFA RCT

	Placebo n=87	FFA 0.2 mg/kg/day n=89	FFA 0.7 mg/kg/day n=87
Diarrhea, n (%)		10 (11.2)	11 (12.6)
Median time to onset, days (range)	NA	9.5 (2–86)	16 (2–86)
% of patients with resolution		90.0%	90.9%
Vomiting, n (%)		12 (13.5)	NA
Median time to onset, days (range)	NA	14 (1–101)	
% of patients with resolution		100%	
Fatigue, n (%)	9 (10.3)		16 (18.4)
Median time to onset, days (range)	4 (1–99)	NA	6.5 (1–41)
% of patients with resolution	66.7%		56.3%
Pyrexia, n (%)	10 (11.5)	9 (10.1)	
Median time to onset, days (range)	28.5 (2–92)	20 (5–92)	NA
% of patients with resolution	100%	100%	
Decreased appetite, n (%)	10 (11.5)	18 (20.2)	31 (35.6)
Median time to onset, days (range)	10 (1–85)	10 (1–69)	11 (1–91)
% of patients with resolution	80.0%	72.2%	45.2%
Somnolence, n (%)	9 (10.3)	9 (10.1)	15 (17.2)
Median time to onset, days (range)	14 (1–96)	17 (1–75)	6 (1–95)
% of patients with resolution	55.6%	77.8%	80.0%


FFA, fenfluramine; NA, not applicable, since the TEAE occurred in <10% of patients in that group; RCT, randomized controlled trial; TEAEs, treatment emergent adverse events.



CONCLUSIONS

First occurrences of TEAEs are reported early in FFA treatment and are associated with high percentages of resolution. FFA continues to be a well-tolerated treatment option for patients with LGS.

Figure. Proportion of Patients With Resolution of First Occurrence of TEAEs Reported in ≥10% of Patients in the FFA OLE



FFA, fenfluramine; OLE, open-label extension; TEAEs, treatment emergent adverse events.

- In the OLE, median time to TEAE onset and percent of patients with resolution of first occurrences were reported for the following TEAEs:
 - Decreased appetite** (n=40): median time to onset, 51.5 days (range, 1–397); resolution in 29 patients (72.5%)
 - Fatigue** (n=33): median time to onset, 60 days (range, 1–362); resolution in 25 patients (75.8%)
 - Nasopharyngitis** (n=31): median time to onset, 87 days (range, 9–360); resolution in 100% of patients
 - Seizure** (n=27): median time to onset, 92 days (range, 1–267); resolution in 22 patients (81.5%)
- Flexible dosing in the OLE limited analysis of time to resolution
- Late-onset first occurrence of TEAEs could be related to other ASMs introduced or dose increases that took place during the OLE study

Conclusions

- These results provide further insight on TEAEs reported by ≥10% of patients in the LGS clinical trials
- Incidence of first onset of TEAEs was most common during the RCT titration phase and the flexible dose phase in the OLE
- Resolution was reported in a high proportion of patients regardless of FFA dose received in either the RCT or OLE
- These data demonstrate that FFA is generally well tolerated, which may positively contribute to health-related quality of life outcomes in patients with LGS

References


- Gastaut H, et al. *Epilepsia*. 1966;7(2):139–79.
- Cross JH, et al. *Front Neurol*. 2017;8:505.
- Strzelczyk A, Schubert-Bast S. *CNS Drugs*. 2021;35(1):61–83.
- UCB Inc. FINTEPLA® (fenfluramine) oral solution [prescribing information]. Smyrna, GA; March 2023.
- UCB. Fintepla 2.2 mg/mL oral solution (summary of product characteristics). Bruxelles, BE; 2024.
- UCB Pharma LTD. Fintepla 2.2 mg/ml oral solution [summary of product characteristics]. Slough, Berkshire; April 2024.
- UCB Pharma S.A. 2024. <https://israelidrug.health.gov.il/#!/medDetails/169%2041%2036976%2099>.
- Nippon Shinyaku Co. Ltd. 2024. https://www.nippon-shinyaku.co.jp/file/download.php?file_id=7484.
- Knupp K, et al. *JAMA Neurol*. 2022;79(6):554–64.
- Knupp KG, et al. *Epilepsia*. 2023;64(1):139–51.
- Data on file. UCB; 2024.

Acknowledgements

UCB-sponsored. The authors acknowledge Vincent Laporte, PhD (UCB), for managing the development of the poster, and Sandra M Aguero, PharmD, BCPS, and Scott Bergfeld, PhD, of PharmaWrite, LLC (Princeton, NJ, USA), for writing and editorial assistance, which was funded by UCB.

Disclosures

LL: Research grants, consultant and/or speaker: Eisai, Epilunther, LivaNova, Novartis, Shire, UCB, Zogenix (now a part of UCB). **JS:** Research grants: Biopharm, Marinus, Stoke, Zogenix (now a part of UCB); Consultant/Advisor: Asceneuron, Dravet Syndrome Foundation, Encoded, Epygenix, GW Pharma (now Jazz Pharmaceuticals), Knopp Biosciences, Longboard, Neurocrine; Stock options: Epygenix; Travel support: Zogenix (now a part of UCB); Reviewer: Epilepsy Study Consortium. **RS:** Grants or contracts: DDD and NINDS; Book royalties: Cambridge University Press and Elsevier; Consulting fees: Aguestive, Eisai, and UCB; Payment or honoraria for lectures, seminars, speakers bureaus, manuscript writing, or educational events: Aquestive, BioMarin, Jazz Pharmaceuticals, Neurilis, SK Life Science, UCB, and Zogenix (now a part of UCB); Data Safety Monitoring Board: Takeda. **KGK:** Research grants: Encoded, Stoke, Zogenix (now a part of UCB); Consultant: Biocodex, Biomarin, Epygenix; Other support as a Data and Safety Monitoring Board member: Epygenix, Jazz Pharmaceuticals. **SMZ:** Research support: Dravet Syndrome UK, Epilepsy Research UK, and Zogenix (now a part of UCB); Consultant/Speaker and advisory board member: Anville, Eisai, Encoded Therapeutics, GW Pharma (now Jazz Pharmaceuticals), Jaguar Gene Therapy, Stoke Therapeutics, UCB, and Zogenix (now a part of UCB). **AGN:** Speakers bureau, advisory boards, or committees: Angelini Pharma, Bial, Biocodex, Eisai, Esteve, GW Pharma (now Jazz Pharmaceuticals), Orlis 4 Cure, Pharvaris, PTC Therapeutics, Rapport Therapeutics, Stoke, UCB Pharma, and Zogenix (now a part of UCB Pharma); Research support from Biogen, Jazz Pharmaceuticals, PTC Therapeutics, and UCB Pharma. **IES:** Scientific advisory boards: Biopharm, Chiesi, Eisai, Encoded, GlaxoSmithKline, Knopp Biosciences, Longboard, Nutricia, Takeda Pharmaceuticals, UCB, Xenon; Speaker honoraria: Akumetis, Biocodex, Biomarin, Chiesi, Eisai, GlaxoSmithKline, Liva Nova, Nutricia, Praxis, Stoke, UCB, Zuellig Pharma; Travel support: Biocodex, Biomarin, Eisai, Encoded, GlaxoSmithKline, Longboard, Stoke, UCB; Investigator, Anavex Life Sciences, Cerevel, Eisai, Encoded, EpiMinder, Epygenix, ES-Therapeutics, GW Pharma (now Jazz Pharmaceuticals), Longboard, Marinus, Neurocrine Biosciences, Ovid, SK Life Science, Takeda, UCB, Ultragenyx, Xenon, Zogenix (now a part of UCB). **Zynerba:** Consultant: Atheneum Partners, Biohaven, BioMarin, Care Beyond Diagnosis, Encoded, Epilepsy Consortium, Ovid, Praxis, Stoke, UCB, Zynerba; Non-Executive Director of Belberrry Ltd. and Director of the Australian Academy of Health and Medical Sciences; May accrue future revenue: pending patent WO61/010176 (filed: 2008): Therapeutic Compound; a patent for SCN1A testing held by Biomedics Inc and licensed to various diagnostic companies; a patent molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) (P/RRT2) 2011904493 & 2012900190 and PCT/AU2012/001321 (TECH ID:2012-009). **RG:** Research grants: Zogenix (now a part of UCB) during conduct of the study; Speaker/Consultant, Zogenix (now a part of UCB), outside the submitted work; Investigator: Angelini, Biocodex, Eisai Inc, UCB; Speaker/Advisory Boards: Biocodex, Biomarin, GW Pharma, outside the submitted work, Novartis. **AS:** Personal fees and grants: Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, UCB, and UNEG medical. **KR:** Honoraria for educational symposia, advisory boards, and/or consultancy work: Eisai, LivaNova, Medix, Novartis, and UCB Australia; Clinical trials (supported by her institution): Biogen Idec Research, DSLP, Eisai, Epygenix Therapeutics, GW Research, Janssen-Cilag, LivaNova, Longboard Pharmaceuticals, Marinus Pharmaceuticals, Medix International, Neurocrine Biosciences, Noema Pharma, Novartis, SK Lifesciences, Takeda Pharmaceutical Company Limited, UCB Australia, UCB Biopharma, and Zogenix (now a part of UCB). **PH, JA, HL, AL:** Employees and stock ownership: UCB. **RN:** Research funding: Eisai, GW Pharma (now Jazz Pharmaceuticals), Novartis, UCB, and Zogenix Inc (now a part of UCB); Consultant/Advisor: Biogen, Eisai, GW Pharma (now Jazz Pharmaceuticals), Novartis, Shire, and Zogenix Inc (now a part of UCB); Speaker: Advicenne, BioMarin, Eisai, GW Pharma (now Jazz Pharmaceuticals), Novartis, and Zogenix Inc (now a part of UCB).



Previously presented at American Epilepsy Society 78th Annual Meeting
Los Angeles, CA, USA | 6–10 December 2024
**Presented at the 16th European Paediatric Neurology Society Congress
Munich, Germany | 8–12 July 2025**

- Table 2** describes median time to onset and duration of first occurrences of TEAEs reported in ≥10% of RCT patients
 - Decreased appetite and somnolence occurred in ≥10% of patients in all RCT groups (placebo and FFA)
 - Of the FFA groups, earliest median time to onset of TEAEs occurred in patients treated with FFA 0.7 mg/kg/day with somnolence (n=15; median, 6 days; range, 1–95) and fatigue (n=16; median, 6.5 days; range 1–41)
 - First occurrence of pyrexia and vomiting resolved in all patients
 - Vomiting resolved in 12/12 patients on FFA 0.2 mg/kg/day within a median duration of 1.5 days (range, 1–54)
 - Pyrexia resolved in 10/10 patients in the placebo group within a median of 2.5 days (range, 1–6) and in 9/9 patients treated with FFA 0.2 mg/kg/day within a median of 3 days (range, 1–10)
- Resolution occurred in 45.2%–100% of patients for whom a TEAE occurring in ≥10% patients was reported while on FFA


Table 2. Median Time to Onset and Duration of First Occurrences of TEAEs Reported in ≥10% of Patients in the FFA RCT by Dose Group

		Diarrhea		Vomiting		Fatigue		Pyrexia		Decreased Appetite		Somnolence	
		Onset	Duration	Onset	Duration	Onset	Duration	Onset	Duration	Onset	Duration	Onset	Duration
Placebo n=87	n Median, days (range)	NA	NA	NA	NA	9 4 (1–99)	6 20.5 (3–71)	10 28.5 (2–92)	10 2.5 (1–6)	10 10 (1–85)	8 28 (8–65)	9 14 (1–96)	5 37 (4–42)
FFA 0.2 mg/kg/day n=89	n Median, days (range)	10 9.5 (2–86)	9 2 (1–60) ^a	12 14 (1–101)	12 1.5 (1–54) ^a	NA	NA	9 20 (5–92)	9 3 (1–10)	18 10 (1–69)	13 15 (4–98)	9 17 (1–75)	7 18 (1–42)
FFA 0.7 mg/kg/day n=87	n Median, days (range)	11 16 (2–86)	10 5 (1–32)	NA	NA	16 6.5 (1–41)	9 51 (4–101)	NA	NA	31 11 (1–91)	14 25.5 (4–97)	15 6 (1–95)	12 14.5 (4–75)


^aThe maximum end of the range was due to one patient.

FFA, fenfluramine; LGS, Lennox-Gastaut syndrome; NA, not applicable, since the TEAE occurred in <10% of patients in that group; OLE, open-label extension; RCT, randomized controlled trial; TEAEs, treatment emergent adverse events.

A. In the RCT (N=263)^{a,b}



B. By Flexible Dose in the OLE (N=247)^c



^aTEAEs reported in ≥10% of patients in either treatment group were: decreased appetite, somnolence, fatigue, pyrexia, diarrhea, and vomiting. ^bTEAEs reported in 2 patients on the last day of FFA treatment in the RCT, a few days beyond 14 weeks (98 days), which accounts for TEAEs listed at Week 15. ^cTEAEs reported in ≥10% of patients were: decreased appetite, fatigue, nasopharyngitis, and seizure; there were no first occurrences of these after Week 57. FFA, fenfluramine; OLE, open-label extension; PBO, placebo; RCT, randomized controlled trial; TEAEs, treatment emergent adverse events.